Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | TXN | P10599 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 7/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28695956 | 0.92 | MAPT (0.43) | MAPTALDH1A1TDP1MAPK13CDK1 | |
| SCHEMBL7855617 | 0.83 | MAPT (0.39) | MAPTALDH1A1TDP1 | |
| SCHEMBL102964 | 0.83 | KDM4E (0.35) | MAPTALDH1A1GPR84 | |
| SCHEMBL205009 | 0.83 | MAPK13 (0.48) | MAPTALDH1A1MAPK13CDK1PIM1 | |
| SCHEMBL14730924 | 0.78 | — | — | |
| SCHEMBL1021150 | 0.78 | GRIN2D (0.44) | ALDH1A1MAPK13CDK1PIM1DYRK1A | |
| SCHEMBL9307669 | 0.76 | MAPK13 (0.37) | MAPK13CDK1PIM1DYRK1APIM3 | |
| SCHEMBL12180644 | 0.76 | MAPT (0.35) | MAPTALDH1A1TDP1 | |
| SCHEMBL2589396 | 0.76 | EGLN1 (0.34) | EGLN1 | |
| SCHEMBL26449991 | 0.76 | DAO (0.35) | MAPTTDP1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117242047-A | Process for the vapor phase hydrogenation of aldehydes | 陶氏技术投资有限责任公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2022250790-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| US-9573870-B2 | Hetereocyclic agent as catalytic stabilizing agent in a hydroformylation process | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2015-12-31 | — | — | US | disclosed |
| EP-0873292-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | NUDT1, CAT, HRAS | MAPT 4148/4885ALDH1A1 1425/4885TDP1 2238/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | MAPT 1565/4885ALDH1A1 7/4885TDP1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.